期刊文献+

5%咪喹莫特乳膏每日1次治疗尖锐湿疣68例

Effects of 5% imiquimod cream once a day in 68 patients with condyloma acuminatum
原文传递
导出
摘要 目的观察5%咪喹莫特乳膏每日一次治疗尖锐湿疣的疗效。方法尖锐湿疣患者98例,分为2组。试验组68例,每日患处直接外用足量5%咪喹莫特乳膏一次,共4 wk。对照组30例,隔日患处直接外用足量5%咪喹莫特乳膏一次,共8 wk。观察治疗前后疣体发生的部位、数目、形状、大小及用药后局部刺激和全身不良反应。结果试验组退出1例,治疗4 wk后有效率为69%(46/67),对照组治疗8 wk后有效率为73%(22/30),2组疗效无显著差异(P>0.05)。试验组疣体消退时间为(12.5±6.5)d,对照组为(40.5±12.2)d,试验组短于对照组,差异有显著意义(P<0.05)。试验组不良反应发生率为50%,对照组为40%,无显著差异(P>0.05)。结论 5%咪喹莫特乳膏每日一次治疗尖锐湿疣疗效与隔日一次相当,可缩短疗程。 AIM To study the effects of 5% imiqfiimod cream once a day on condyloma acuminatum. METHODS A total of 98 patients with condyloma acuminatum were assigned to trial group (n = 68) and control group (n = 30), and were respectively administered with 5% imiquimod cream once a day for 4 wk and 5% imiquimod cream once two days for 8 wk. Anatomic site of the wart, wart number, wart morphology, wart size and adverse reactions were observed. RESULTS The effective rates of the trial group and the control group were 69% (46/67) and 73% (22/30) at the end of the treatment, respectively. There was no significant difference in clinical effect between two groups (P 〉 0.05) . Wart regression time of the trial group was (12.5 ± 6.5)d, shorter than that of the control group ((40.5 ± 12.2)d, P 〈 0.05). There was no significant difference in the incidence of local adverse reactions (50% in the trial group and 40% in the control group, P 〉 0.05). No serious adverse reactions occurred. CONCLUSION In the treatment of condyloma acuminatum, 5% imiquimod cream once a day is effective as 5% imiquimod cream once two days, and can shorten the course of treatment.
作者 张怡明 孙婕
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2011年第9期673-675,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 咪喹莫特 尖锐湿疣 投药 皮肤 imiquimod condyloma acuminata administration, cutaneous
  • 相关文献

参考文献6

二级参考文献19

  • 1朱学骏,孔繁荣,季素珍,白义杰,李正刚,吴长山.尤脱欣与疣敌治疗尖锐湿疣的疗效比较[J].中华皮肤科杂志,1994,27(3):199-200. 被引量:7
  • 2杨文彪,徐广坤.CO_2激光浅表凝固法治疗外生殖器尖锐湿疣[J].中华皮肤科杂志,1994,27(3):174-174. 被引量:16
  • 3GOLLNICK H,BARASSO R,JAPPE U, et al. Safety and efficacy of imiquimod 5 % cre am in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once perday[J]. Int J STD AIDS,2001,12(1):22-28.
  • 4TIAN HQ, DU DH.Imiquimod in treatment of condylomata cuminatum[J].Chin J New Drug Clin Rem(in Chinese),2003,22(3):180-182.
  • 5BEUTNER KR, SPRUANCE SL, HOUGHAM AJ et al. Treatment of genital war ts with an immune response modifier(imiquimod)[J].J Am Acad Dermatol,1998,38(2 Pt 1):230-239.
  • 6IMBERTSON LM,BEAURLINE JM,COUTURE AM,et al. Cytokine induction in ha irless mouse and rat skin after topical application of the immune response modifier s imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.
  • 7TYRING S.Immune response modification: imiquimod[J]. Aust J Dermatol, 1998,39 Supp1:S11-S13.
  • 8EDWARDS L. Imiquimod in clinical practice[J].Aust J Dermatol,1998,39 Su ppl1:S14-S16.
  • 9Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cretan: a placebo-controlled, double-blind study. J Dermatol, 1998 , 25: 648-652.
  • 10Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs, 1999 , 58: 375-390.

共引文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部